Excretion of hippuric acid during sodium benzoate therapy in patients with hyperglycinaemia or hyperammonaemia.
In patients with non-ketotic hyperglycinaemia and two patients with urea cycle disorders treated with varying doses of sodium benzoate there was linear correlation between intake of benzoate and excretion of hippurate. Patients with non-ketotic hyperglycinaemia excreted significantly more benzoate in the form of hippurate than patients with urea cycle disorders (74 +/- 7.0 vs 41 +/- 3.6%). The plasma concentration of glycine decreased following benzoate treatment only in the patients with non-ketotic hyperglycinaemia. The observed difference between the two groups in the excretion of hippurate seems to support the concept that glycine availability may be limiting in benzoate therapy for some patients.
Barshop
B A
BA
Department of Pediatrics, University of California San Diego, La Jolla 92093.
Breuer
J
J
Holm
J
J
Leslie
J
J
Nyhan
W L
WL
D000592:Amino Acid Metabolism, Inborn Errors / Q000188:drug therapy / Q000652:urine; D000641:Ammonia / Q000097:blood*; D001565:Benzoates / Q000627:therapeutic use*; D019817:Benzoic Acid; D002675:Child, Preschool; D005260:Female; D005998:Glycine / Q000097:blood*; D006626:Hippurates / Q000652:urine; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008661:Metabolism, Inborn Errors / Q000188:drug therapy* / Q000652:urine
D001565:Benzoates; D006626:Hippurates; D000641:Ammonia; D019817:Benzoic Acid; C030514:hippuric acid; D005998:Glycine